A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
Recruiting · Phase 1 · NCT05765851
Conditions: Advanced Solid Tumor
At a glance
- Research payments reported, 2025
- $1.2M
- U.S. investigators named
- 4
- Sites paid
- 5
- Planned or actual enrollment
- 128
About the trial
- Sponsor
- Daiichi Sankyo (with AstraZeneca)
- Tested
- DS-1103a (drug), T-DXd (drug)
- Dates
- Started 2023-05-30; completion 2031-02-28
- Results posted
- Not yet
This study will evaluate the safety and efficacy of DS-1103a combination therapy in participants with advanced solid tumors.
From ClinicalTrials.gov, last updated 2026-10-26. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Daiichi Sankyo Inc. reported $1.2M in research payments for this study in 2025 (736 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Christos Vaklavas, M.D. Hematology & Oncology · Birmingham, AL
- Manish R. Patel, MD Medical Oncology · Sarasota, FL
- Stephanie L. Graff, M.D. Hematology & Oncology · Kansas City, MO
- Alexander I. Spira, M.D. Medical Oncology · Fairfax, VA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Next Oncology-San Antonio $502,794
- Sarah Cannon Research Institute $385,753
- Rhode Island Hospital, RI $229,680
- University of Utah Hospital and Clinics, UT $76,419
- Florida Cancer Specialists and Research Institute Sarasota Cattlemen $4,917
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.